Sunnyvale, CA – According to filings with the U.S. Securities and Exchange Commission, Angarus Therapeutics is raising $6,883,438.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nigel Ray played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Angarus Therapeutics

The scientists at Angarus are developing checkpoint blockers on the innate immunity STING pathway. Our preclinical data demonstrate that a combination of checkpoint blockers, both innate and adaptive, leads to long term survival. We plan to develop treatments that benefit patients with a wide-range of cancer types. Our scientists first designed STING agonists and discovered they were effective in treating cold solid tumors in mice by increasing TIL counts. Angarus’s strategy is to target ENPP1 (ecto-nucleotide pyrophosphatase I), a checkpoint of the innate immune STING pathway, differentiating it from all other STING agonists.

To learn more about Angarus Therapeutics, visit http://www.angarustherapeutics.com/

Contact:
Nigel Ray, Chief Executive Officer
650-575-1702
https://www.linkedin.com/in/nigelray/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved